Clinical trials: Differentiated Thyroid Carcinoma
Papillary Thyroid Cancer
Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma
Primary objective: The 3-years disease-free survival was compared between low-dose group (30 mCi) and high-dose group (100 mCi).
- Trial name
- NCT04354324
- Testing
- Radioiodine
- Where
- China
- Volunteers
- 254 people, healthy volunteers welcome
- Sponsor
- Zhujiang Hospital
Thyroid Cancer, Thyroid Nodule
Educational Videos for Thyroid Surgery Patient
The researchers aim to evaluate the performance of two groups of participants after receiving traditional education-one group supplemented with video-based education and the other without.
- Conditions
- Thyroid Cancer, Thyroid Nodule, TSH, Education of Patients
- Trial name
- NCT07823543
- Testing
- Thyroid Surgery Educational Video
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- West China Hospital
Thyroid Nodule
Application of Ultrasonic Gray-scale Ratio in Differentiating Benign From Malignant Thyroid Nodules.
According to the grades of echogenicity to evulated thyroid nodules is a subjective process and is thus influenced by the observer's judgement.
- Trial name
- NCT03700762
- Testing
- ultrasound gray-scale ratio
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- First People's Hospital of Hangzhou
Thyroid Cancer
Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil
This is an Expanded Access Program to make lenvatinib available to participants with radioiodine-refractory differentiated thyroid cancer in Brazil.
- Trial name
- NCT03533361
- Testing
- Lenvatinib
- Where
- Brazil
- Sponsor
- Eisai Inc.
Recurrent Thyroid Gland Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v7
Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer
This phase II trial studies the side effects and how well pazopanib hydrochloride works in treating patients with advanced thyroid cancer.
- Conditions
- Recurrent Thyroid Gland Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v7, Stage III Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7
- Trial name
- NCT00625846
- Testing
- Laboratory Biomarker Analysis, Pazopanib Hydrochloride
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 152 people
- Sponsor
- National Cancer Institute (NCI)